EFFICACY AND SAFETY OF BUDESONIDE/FORMOTEROL IN MODERATE-TO-SEVERE COPD: A RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Main Article Content
Keywords
COPD, Budesonide/formoterol, Exacerbations, Lung function and Quality of life.
Abstract
The purpose of the study was to examine the efficacy and safety of budesonide / formoterol in patients with moderate-severe COPD. We recruited 488 patients and randomized 384 to receive either budesonide/formoterol, budesonide or formoterol over a 12-month period. As a combined treatment with budesonide and formoterol, budesonide/formoterol significantly reduced severe pneumonia attacks by 24 percent compared with placebo, and its effect on FEV1 was 15 percent greater than budesonide or formoterol alone. SGRQ also reported a significant improvement in peak expiratory flow, symptoms, and quality of life with budesonide/formoterol. No difference was found between the treatment groups when it came to negative events. The results of these studies show that budesonide/formoterol relieves exacerbations, improves lung function, and improves patient satisfaction with it.
References
2. GOLD: Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHI publication no. 2701, March 2001.
3. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157: 1418–1422.
4. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1 The Lung Health Study. JAMA 1994; 272: 1497–1505.
5. Scanlon PD, Connett JE, Waller LA, Altose MD, Bailey WC, Buist AS. Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study. Am J Respir Crit Care Med 2000; 161: 381–390.
6. Turato G, Di Stefano A, Maestrelli P, et al. Effect of smoking cessation on airway inflammation in chronic bronchitis. Am J Respir Crit Care Med 1995; 152: 1262–1267.
7. Rutgers SR, Postma DS, Hacken NH, et al. Ongoing airway inflammation in patients with COPD who do not currently smoke. Thorax 2000; 55: 12–18.
8. Cazzola M, Donner CF. Long-acting b2-agonists in the management of stable chronic obstructive pulmonary disease. Drugs 2000; 60: 307–320.
9. Boyd G, Morice AH, Pounsford JC, Siebert M, Peslis N, Crawford C. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10: 815–821.
10. Wadbo M, Lo¨fdahl CG, Larsson K, et al. A placebocontrolled comparison of the effects of formoterol and ipratropium bromide in patients with COPD. Eur Respir J 1999; 14: Suppl. 30, 381s.
11. Jones PW, Bosch TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155: 1283–1289.
12. Greefhorst APM, Dahl R, Nowak D, et al. for the FICOPD I study group. Effect of inhaled formoterol and ipratropium bromide on quality of life, "bad days" and exacerbations in patients with COPD. Am J Respir Crit Care Med 2000; 161: A490.
13. C¸ elik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: A crossover, placebo-controlled comparison of onset and duration of action. Respiration 1999; 66: 434–439.
14. Cazzola M, Centanni S, Regorda C, et al. Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPD. Pulm Pharmacol Ther 2001; 14: 41–45.
15. Paggiaro PL, Dahl R, Bakran I, Frith L, Hollingworth K, Efthimiou J. Multicentre, randomized placebocontrolled trial of inhaled fluticasone propionate in patients with chronic obstructive pulmonary disease. Lancet 1998; 351: 773–780.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Kotla Ankith
Assistant Professor, Department of Respiratory Medicine, Sri Lakshmi Narayana Institute of Medical Sciences & Hospital, Osudu, Agaram Village, Koodapakkam Post, Puducherry - 605502
